12.07.2016 23:31:50
|
FDA Removes Clinical Hold On Juno Therapeutics' Cancer Drug Trial, Shares Up 27%
(RTTNews) - Juno Therapeutics Inc. (JUNO), a biopharmaceutical company focused on treatment of cancer, Tuesday said the U.S. Food and Drug Administration has removed the clinical hold on its mid-stage clinical trial of JCAR015, a cancer drug.
Under the revised protocol, the trial will continue enrollment using JCAR015 with cyclophosphamide pre-conditioning only.
The FDA had put the clinical trial on a hold after two patients died last week. The deaths followed the recent addition of fludarabine to the pre-conditioning regimen.
Following the news, shares of Juno surged 27.74% in the after-hours trading.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Juno Therapeutics Incmehr Nachrichten
Keine Nachrichten verfügbar. |